The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10329
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
University of Texas MD Anderson Cancer Center LAO
Yap, Timothy Anthony
(713) 563-1784
Phase I – PBTC-056
A Phase I Study of the ADAM-10 Inhibitor, INCB7839 in Children with Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
Pediatric Brain Tumor Consortium
Monje, Michelle
(650) 736-0885
Phase I/II – 10221
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors
University of Texas MD Anderson Cancer Center LAO
Yap, Timothy Anthony
(713) 563-1784
Phase II – 10264
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Yale University Cancer Center LAO
Prebet, Thomas
(203) 737-7103
Phase II – ADVL18P1
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation
Children’s Oncology Group
Zarnegar-Lumley, Sara
(615) 936-1762
Phase II – APEC1621K
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
Children’s Oncology Group
Alva, Elizabeth Duncan
(205) 638-9285
Phase III – AAML1831
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Children’s Oncology Group
Cooper, Todd Michael
(206) 987-2106
Phase III – S1914
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
SWOG
Daly, Megan Eileen
(916) 734-5428
